Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ETSAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Capricor ...

Capricor Therapeutics (CAPR) shares soared 12% in the last trading session to close at $6.92. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. Given this risk, we thought we'd take a look at whether Capricor Therapeutics (NASDAQ:CAPR) ...

Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. BOSTON — Replimune Group and ...

LOS ANGELES, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) investors of a class action representing investors ...

High-rolling investors have positioned themselves bearish on Capricor Therapeutics (NASDAQ:CAPR), and it's important for retail traders to take note. \This activity came to our attention today through ...

Deramiocel, the lead product candidate, is still in late-stage development and has not yet received regulatory approvals, which raises concerns about the company's ability to bring products to market.

(RTTNews) - Biotechnology company Capricor Therapeutics (CAPR) Thursday announced the completion of the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration ...

Capricor Therapeutics (CAPR) shares soared 5.3% in the last trading session to close at $6.52. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...